Research

The University of Arizona is not eligible to apply to the 2026 Beckman Scholars Program due to an existing award. 

If you have any questions, please contact RDS.

Request Ticket // Limit: 1 // Tickets Avaialbe: 1

The University of Arizona Cancer Center (UACC) can nominate one individual for the 2026 Pew-Stewart Scholars for Cancer Research program. For more information please contact: UACC-PreAward.

In line with The Stewart Trust’s mission to invest in innovative, cutting-edge cancer research that may accelerate and advance progress toward a cure for cancer, applications are invited from nominees conducting cancer research at NCI-designated cancer centers, or cancer-focused institutions. The Pew-Stewart Scholars Program for Cancer Research is distinct from the Pew Scholars Program, and it follows a different, but parallel set of guidelines and procedures for nominating an applicant whose research is related to cancer.

In early April 2025, a letter of invitation and application instructions will be sent to the leaders of the cancer research institutions selected to submit a nominee for the 2026 class. Centers are expected to complete a limited submission competition in order to identify and select one nominee. For guidance on this process, please contact Pew-Stewart@pewtrusts.org.

• Center administration should distribute this invitation and award eligibility details to all investigators via an email announcement or website posting.
• Interested applicants should submit pre-proposal material to an internal selection committee for consideration.
• To nominate a candidate, a member of the internal selection committee must complete an online survey from the Pew program office describing the selection process used by the institution and submit the name and contact information of the chosen applicant by May 14, 2025.
• Nominations of applicants to the program will not be considered after May 14, 2025.
• The Pew program office will email grant application portal login information and a detailed application guide directly to all nominated applicants by June 11, 2025. The online application website will open on June 11, 2025.
• For research administrators assisting an applicant, please send an email with your grant applicant cc’ed to Pew-Stewart@pewtrusts.org after June 11, 2025, to receive access to the portal. No requests will be accepted prior to this date.
• The application submission deadline is Aug. 27, 2025.
• Every application will be reviewed by the program's National Advisory Committee. The committee will make recommendations to the board of directors of The Pew Charitable Trusts in April 2026. Candidates will be notified in April if they have been recommended to the Stewart and Pew boards.
• A public announcement of the award will be made in June. Grant agreements will be issued to the grant hosting institution of each scholar in August of the award year.

Apply to Internal Competition // Limit: 2 (1 Translational nominee, 1 All-Star Translational nominee) // Tickets Available: 2 

The University of Arizona Cancer Center (UACC) can nominate up to two proposals: one Translational nominee and one All-Star Translational nominee (if eligible) for the V Foundation Adult Translational Cancer Research Award 2025. 

For more information please contact: UACC-PreAward.

Purpose of Award:

The UACC is seeking nominations for the Translational Adult Cancer Research Grant which advances basic laboratory discoveries towards clinical use, ultimately improving human health and is restricted to adult cancer research.

This Translational grant is restricted to adult cancer research in the preclinical or translational space with a focus on bench-to-bedside strategies. Research on ANY adult cancer type can be funded. Applicants may propose cancer research that moves a novel strategy from the laboratory into a human clinical trial or uses specimens from a clinical trial to test hypotheses, develop biomarkers, or mechanisms. The research must apply in a direct way to human beings within 3 years from the end of the grant. If biomarker research is undertaken, a validation set or independent clinical trial is essential. A plan for biomarker validation, if applicable, must be included in any proposal. The endpoint of the project should be the planning or initiation of a new clinical trial or conducting an investigator-initiated trial with laboratory correlates that test hypotheses. Research areas not included in this scope are epidemiology, behavioral science, and health services research.

Limit: 1 per SIP

K. Ellingson (Public Health) for SIP25-005 Understanding the potential of early childcare and education (ECE) centers in promoting childhood vaccines and RSV prevention products

S. Carvajal (College of Public Health's Prevention Research Center) for SIP25-006 Overdose Prevention and Treatment Research Network (OPTRN)

Eligibility: 
Only one application per SIP per institution is allowed (e.g., multiple applications for the same SIP (listed in Section VIII) from the same institution are NOT permitted).

Purpose:
This Notice of Funding Opportunity (NOFO) invites applications from CDC Health Promotion and Disease Prevention Research Centers (PRCs), selected for funding under RFA-DP-24-004, to apply for supplemental funding to conduct Special Interest Research Projects (SIPs) to inform public health practice. PRCs will conduct high-quality applied health promotion and disease prevention research projects in real-world settings to identify, design, test, evaluate, disseminate, and translate interventions (i.e., programs, practices, policies, or strategies) to prevent and reduce risk for the leading causes of illness, disability, and death in the United States.

Request Ticket // Limit: 2 // Tickets Available: 2

Number of Applications
The NIH will not accept duplicate or highly overlapping applications under review at the same time, per 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:

• A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
• A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
• An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Two applications per institution (with a Unique Entity Identifier ) and a unique NIH eRA Institutional Profile File (IPF) number) are allowed per review round. The same or a similar topic may be submitted for subsequent review rounds involving the same or a similar team, but must be presented as a New application, not a Resubmission.

Applications that are not considered to be within the NIGMS mission will not be reviewed. Eligibility and appropriateness to the NIGMS mission will be evaluated again after review and prior to funding. Applications outside the NIGMS mission will not be funded. Given that only two applications are permitted per institution per review round, it is important to contact NIGMS staff before committing to any particular team and its topic area.

Purpose: 
This Funding Opportunity Announcement (FOA) is designed to support highly integrated research teams of three to six Program Directors/Principal Investigators (PDs/PIs) to address ambitious and challenging research questions that are within the mission of NIGMS. Project goals should not be achievable with a collection of individual efforts or projects. Collaborative program teams are expected to accomplish goals that require considerable synergy and managed team interactions. Teams are encouraged to consider far-reaching objectives that will produce major advances in their fields.

This FOA is not intended for applications that are mainly focused on the creation, expansion, and/or maintenance of community resources, creation of new technologies, or infrastructure development.

Limit: 1 // Tickets Available: 0
Q. Hao (Aerospace & Mechanical Engineering) 

Eligibility 
One (1) per organization as lead institution.

The scientific focus of the MIP program is subject to change from competition to competition. Information about the existing MIPs, from two previous competitions in 2015 and 2019, can be found at mip.org. The third MIP competition, in 2025, will accept proposals on alloys, amorphous, and composite materials. Given that the second MIP competition included an emphasis on biomaterials and polymer research, proposals mainly on these topics will not be considered in the third MIP competition.

RFA Withdrawn // Limit: 1 // Tickets Available: 1 

Duplicate or Multiple Submissions – submission of duplicate or predominantly overlapping applications is not allowed. NIFA will disqualify both applications if an applicant submits multiple applications that are duplicative or substantially overlapping to NIFA programs within the same RFA fiscal year. 

The National Institute of Food and Agriculture’s Agricultural Genome to Phenome Initiative (AG2PI), Assistance Listing 10.332, is intended to:  
1. Study agriculturally significant crops and animals in production environments to achieve sustainable and secure agricultural production. 
2. Ensure that current gaps in existing knowledge of agricultural crop and animal genetics and phenomics are filled. 
3. Identify and develop a functional understanding of relevant genes from animals and agronomically relevant genes from crops that are of importance to the agriculture sector of the United States. 
4. Ensure future genetic improvement of crops and animals of importance to the agriculture sector of the United States. 
5. Study the relevance of diverse germplasm as a source of unique genes that may be of importance in the future. 
6. Enhance genetics to reduce the economic impact of pathogens on crops and animals of importance to the agriculture sector of the United States. 
7. Disseminate findings to relevant audiences.  

Limit: 2 // Tickets Available: 0

M. Phillips (Optical Sciences)
B. Parent (Aerospace and Mechanical Engineering)

Executive Summary
The FES Discovery Plasma Science: Plasma Science and Technology–General Plasma Science (GPS) program seeks new or renewal single-investigator or small-group applications to carry out hypothesis-driven frontier-level research in basic plasma science and engineering. This program aims to develop accurate descriptions of the complex behavior of the plasma state, to push it into new regimes that expand our concept of what constitutes a plasma, to design experiments and diagnostics to explore these states, and to validate theoretical models. 

For more information, see GPS program science drivers in the CPP Report: A Community Plan for Fusion Energy and
Discover Plasma Sciences, 2019-2020. This NOFO is focused on fundamental research involving plasma including astrophysical, dusty, and low temperature plasmas. Research toward developing plasma-based technologies is out of scope of this NOFO.

Limitations on Submissions 
Applicant institutions are limited to no more than two pre-applications (or lead applications), and PIs may only be named on no more than one pre-application (or lead application).

Individuals named as DOE/NNSA National Laboratory PIs, Co-PIs, or senior/key personnel must be an indispensable part of the laboratory with their effort closely integrated into the laboratory’s current plasma science research program and supported at least 50% of their time by the laboratory.

If a multi-institutional team is submitting collaborative applications, only the lead institution should submit a pre-application that should include all institutions, institutional Co-PIs, and all other personnel and relevant information.

DOE will consider the latest received submissions to be the institution’s intended submissions.
• Pre-applications in excess of the limited number of submissions will be discouraged.
• Applications in excess of the limited number of submissions will be declined without review.

Limit: 2 // Available: 0
Y. Bai (Optical Sciences)
S. Kong (Astronomy) 
 

Eligibility: 

Must be a faculty members in the first three years of their faculty careers, that is, whose initial faculty appointments began no earlier than May 31, 2022, and no later than May 31, 2025.
 

The  Packard Fellowships for Science and Engineering Program invests in future leaders who have the freedom to take risks, explore new frontiers in their fields of study, and follow uncharted paths that may lead to groundbreaking discoveries.

Candidates must be faculty members who are eligible to serve as principal investigators engaged in research in the natural and physical sciences or engineering and must be within the first three years of their faculty careers. Disciplines that will be considered include physics, chemistry, mathematics, biology, astronomy, computer science, earth science, ocean science, and all branches of engineering. Candidates engaged in research in the social sciences will not be considered. 

The Fellowship Program provides support for highly creative researchers early in their careers; faculty members who are well-established and well-funded are less likely to receive the award.  Packard Fellows are inquisitive, passionate scientists and engineers who take a creative approach to their research, dare to think big, and follow new ideas wherever they lead.  

The Foundation emphasizes support for innovative individual research that involves the Fellows, their students, and junior colleagues, rather than extensions or components of large-scale, ongoing research programs.  
 

No Applicants // Limit: 5 // Tickets Available: 5

The University of Arizona Cancer Center (UACC) can nominate five applications for the Damon Runyon Clinical Investigator Award. 

For more information please contact: UACC-PreAward.

Purpose of Award 

The Damon Runyon Clinical Investigator Award supports independent young physician-scientists conducting disease-oriented research that demonstrates a high level of innovation and creativity. The goal is to support the best young physician-scientists doing work aimed at improving the practice of cancer medicine.

The Clinical Investigator Award responds to three recognized realities:

• Though there has never been a more pressing need or more promising time for clinical cancer research, fewer young physicians enter this area of investigation every year.
• The number of institutions committed to training young physicians in the scientific discipline and methodologies of clinical investigation is critically low.
• The burden of medical school debt (averaging over $100,000) discourages many physicians from pursuing clinical investigation.

The Damon Runyon Cancer Research Foundation’s award offers solutions to these realities. The awardee will receive financial support for three years, as well as assistance with certain research costs such as the purchase of equipment. The Foundation will also retire up to $100,000 of any medical school debt still owed by the awardee.

The Clinical Investigator Award program is specifically intended to provide outstanding young physicians with the resources and training structure essential to becoming successful clinical investigators. The goal is to increase the number of physicians capable of moving seamlessly between the laboratory and the patient’s bedside in search of breakthrough treatments.

Eligibility

• The applicant must hold an independent Assistant Professor position or equivalent at a U.S. institution and is expected to demonstrate significant support from the home institution through a comprehensive start-up package, ample laboratory space, and protected research time, for example.
• The applicant must have received an MD, DO, or MD/PhD degree(s) from an accredited institution, completed their subspecialty training and be U.S. Board eligible.
• The applicant must hold a valid, active U.S. medical license at the time of application.
• The applicant must apply within the first five (5) years of their Assistant Professor or equivalent full faculty appointment (Cut-off date: July 1, 2020). Instructor, Adjunct and/or acting positions are not eligible.
• Candidates holding or awarded R01s (or R01-equivalent grants such as the DP2 and DP5) at the time of application are not eligible to apply.
• The applicant must commit to spending 80% of their time conducting research. [In rare unique circumstances, the CIA Committee may consider an applicant with a very modest reduction of 80% protected time if their Department Chair can provide a compelling reason explaining why a waiver of the 80% requirement should be granted, what percentage of effort will be guaranteed, and what safeguards will be put in place to make sure the individual’s research will not be compromised by their clinical/administrative activities.]
• The applicant is required to apply in conjunction with a Mentor who is established in the field of clinical translational cancer research, cancer prevention and/or epidemiology and can provide the critical guidance needed during the period of the award. No more than two Damon Runyon Clinical Investigators will be funded to work with the same Mentor at any given time (including Co-Mentors).
• Candidates may apply up to two times during this eligibility period.
• Only one application will be accepted from a Mentor per review session (including Co-Mentors).